135 related articles for article (PubMed ID: 33364450)
21. Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer.
Chitmanee P; Tsang Y; Tharmalingam H; Hamada M; Alonzi R; Ostler P; Hughes R; Lowe G; Hoskin P
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):259-265. PubMed ID: 31708350
[TBL] [Abstract][Full Text] [Related]
22. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
[TBL] [Abstract][Full Text] [Related]
23. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.
Rose JN; Crook JM; Pickles T; Keyes M; Morris WJ
Brachytherapy; 2015; 14(3):342-9. PubMed ID: 25727178
[TBL] [Abstract][Full Text] [Related]
24. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life.
Peters M; Maenhout M; van der Voort van Zyp JR; Moerland MA; Moman MR; Steuten LM; van Deursen MJ; van Vulpen M
Radiother Oncol; 2014 Jul; 112(1):77-82. PubMed ID: 24998704
[TBL] [Abstract][Full Text] [Related]
25. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
26. Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy.
Buchser D; Gomez-Iturriaga A; Melcon JI; Casquero F; Llarena R; Cacicedo J; Bilbao P
J Contemp Brachytherapy; 2016 Dec; 8(6):477-483. PubMed ID: 28115952
[TBL] [Abstract][Full Text] [Related]
27. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer.
Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541
[TBL] [Abstract][Full Text] [Related]
28. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the safety and efficacy of high-dose rate brachytherapy for radiorecurrent prostate cancer: a systematic review and meta-analysis.
Shen B; Liu J; Wu D; Guo J
Strahlenther Onkol; 2024 Feb; ():. PubMed ID: 38386054
[TBL] [Abstract][Full Text] [Related]
30. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
31. Computed tomography versus magnetic resonance imaging in high-dose-rate prostate brachytherapy planning: The impact on patient-reported health-related quality of life.
Harris AA; Wu M; Deirmenjian JM; Shea SM; Kang H; Patel R; Fielder D; Mysz ML; Harkenrider MM; Solanki AA
Brachytherapy; 2021; 20(1):66-74. PubMed ID: 33160849
[TBL] [Abstract][Full Text] [Related]
32. Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of
Sutani S; Yorozu A; Toya K; Nishiyama T; Ozu C; Yagi Y; Nakamura K; Saito S
J Contemp Brachytherapy; 2019 Jun; 11(3):201-206. PubMed ID: 31435426
[TBL] [Abstract][Full Text] [Related]
33. Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature.
Kunogi H; Wakumoto Y; Yamaguchi N; Horie S; Sasai K
J Contemp Brachytherapy; 2016 Jun; 8(3):165-72. PubMed ID: 27504124
[TBL] [Abstract][Full Text] [Related]
34. Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy.
Rutenberg MS; Meister M; Amin PP; Hussain A; Naslund MJ; Kwok Y
Brachytherapy; 2016; 15(6):722-729. PubMed ID: 27693225
[TBL] [Abstract][Full Text] [Related]
35. Urinary toxicity after salvage re-irradiation for prostate cancer local failure after definitive radiotherapy: a clinical and dosimetric prognostic factors analysis.
Dipasquale G; Zilli T; Fiorino C; Achard V; Rouzaud M; Miralbell R
J Contemp Brachytherapy; 2022 Jun; 14(3):222-226. PubMed ID: 36199992
[TBL] [Abstract][Full Text] [Related]
36. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study.
Büchser D; Casquero F; Espinosa JM; Perez F; Minguez P; Martinez-Indart L; Suarez F; Gonzalez A; Cacicedo J; San Miguel I; Maleta A; Gomez-Caamaño A; Bilbao P; Gomez-Iturriaga A
Radiother Oncol; 2019 Jun; 135():13-18. PubMed ID: 31015158
[TBL] [Abstract][Full Text] [Related]
37. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy.
Pearse M; Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw A; Cheung P
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):792-8. PubMed ID: 18707818
[TBL] [Abstract][Full Text] [Related]
38. Health-Related Quality of Life and Toxicity After Definitive High-Dose-Rate Brachytherapy Among Veterans With Prostate Cancer.
Harris AA; Yasuda M; Wu MS; Deirmenjian JM; Farooq A; Baldea KG; Flanigan R; Harkenrider MM; Welsh JS; Solanki AA
Fed Pract; 2021 Aug; 38(Suppl 3):S52-S56. PubMed ID: 34733096
[TBL] [Abstract][Full Text] [Related]
39. A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer.
Potharaju M; Subramanaiam R; Venkataraman M; Perumal K; Ramakrishnan B; Vangara R; Reddy S
Cureus; 2015 Aug; 7(8):e303. PubMed ID: 26430577
[TBL] [Abstract][Full Text] [Related]
40. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy.
Tsang YM; Tharmalingam H; Belessiotis-Richards K; Armstrong S; Ostler P; Hughes R; Alonzi R; Hoskin PJ
Radiother Oncol; 2021 May; 158():184-190. PubMed ID: 33639192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
